The effects of anti-inflammatory agents as host-directed adjunct treatment of tuberculosis in humans: a systematic review and meta-analysis.
Adjunctive treatment
Anti-inflammatory agents
Host-directed therapy
Sputum conversion rate
Systematic review & meta-analysis
Tuberculosis
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
26 Aug 2020
26 Aug 2020
Historique:
received:
27
03
2020
accepted:
17
08
2020
entrez:
28
8
2020
pubmed:
28
8
2020
medline:
20
7
2021
Statut:
epublish
Résumé
The potential role of adjunctive anti-inflammatory therapy to enhance tuberculosis (TB) treatment has recently received increasing interest. There is, therefore, a need to broadly examine current host-directed therapies (HDTs) that could accelerate treatment response and improve TB outcomes. This systematic review and meta-analysis included randomised controlled trials of vitamin D and other HDT agents in patients receiving antibiotic treatment for pulmonary TB. Sputum smear conversion rate at 4-8 weeks was the primary outcome. Secondary outcomes included blood indices associated with infectivity and inflammation, chest radiology and incidence of adverse events. Fifty-five studies were screened for eligibility after the initial search, which yielded more than 1000 records. Of the 2540 participants in the 15 trials included in the meta-analysis, 1898 (74.7%) were male, and the age at entry ranged from 18 to 70 years. There was a 38% significantly (RR 1.38, 95% CI = 1.03-1.84) increased sputum smear negativity in patients administered with vitamin D in addition to standard TB treatment than those receiving only the TB treatment. Patients treated with other HDT anti-inflammatory agents in addition to TB treatment also had a 29% significantly increased sputum smear conversion rate (RR 1.29, 95% CI = 1.09-1.563). Lymphocyte to monocyte ratio was significantly higher in the vitamin D treatment groups compared to the controls (3.52 vs 2.70, 95% CI for difference 0.16-1.11, p = 0.009) and (adjusted mean difference 0.4, 95% CI 0.2 -- 0.6; p = 0.001); whilst tumour necrosis factor-alpha (TNF-α) showed a trend towards a reduction in prednisolone (p < 0.001) and pentoxifylline (p = 0.27) treatment groups. Vitamin D and N-acetylcysteine also accelerated radiographic resolution in treatment compared to placebo at 8 weeks. No differences were observed in the occurrence of adverse events among all HDT treatments. Vitamin D and other anti-inflammatory HDT medications used as adjunct TB treatment may be well tolerated and effective. They significantly improved sputum smear conversion rate and chest radiological appearance, and also exhibited an inflammation resolution effect.
Sections du résumé
BACKGROUND
BACKGROUND
The potential role of adjunctive anti-inflammatory therapy to enhance tuberculosis (TB) treatment has recently received increasing interest. There is, therefore, a need to broadly examine current host-directed therapies (HDTs) that could accelerate treatment response and improve TB outcomes.
METHODS
METHODS
This systematic review and meta-analysis included randomised controlled trials of vitamin D and other HDT agents in patients receiving antibiotic treatment for pulmonary TB. Sputum smear conversion rate at 4-8 weeks was the primary outcome. Secondary outcomes included blood indices associated with infectivity and inflammation, chest radiology and incidence of adverse events.
RESULTS
RESULTS
Fifty-five studies were screened for eligibility after the initial search, which yielded more than 1000 records. Of the 2540 participants in the 15 trials included in the meta-analysis, 1898 (74.7%) were male, and the age at entry ranged from 18 to 70 years. There was a 38% significantly (RR 1.38, 95% CI = 1.03-1.84) increased sputum smear negativity in patients administered with vitamin D in addition to standard TB treatment than those receiving only the TB treatment. Patients treated with other HDT anti-inflammatory agents in addition to TB treatment also had a 29% significantly increased sputum smear conversion rate (RR 1.29, 95% CI = 1.09-1.563). Lymphocyte to monocyte ratio was significantly higher in the vitamin D treatment groups compared to the controls (3.52 vs 2.70, 95% CI for difference 0.16-1.11, p = 0.009) and (adjusted mean difference 0.4, 95% CI 0.2 -- 0.6; p = 0.001); whilst tumour necrosis factor-alpha (TNF-α) showed a trend towards a reduction in prednisolone (p < 0.001) and pentoxifylline (p = 0.27) treatment groups. Vitamin D and N-acetylcysteine also accelerated radiographic resolution in treatment compared to placebo at 8 weeks. No differences were observed in the occurrence of adverse events among all HDT treatments.
CONCLUSIONS
CONCLUSIONS
Vitamin D and other anti-inflammatory HDT medications used as adjunct TB treatment may be well tolerated and effective. They significantly improved sputum smear conversion rate and chest radiological appearance, and also exhibited an inflammation resolution effect.
Identifiants
pubmed: 32847532
doi: 10.1186/s12931-020-01488-9
pii: 10.1186/s12931-020-01488-9
pmc: PMC7448999
doi:
Substances chimiques
Anti-Bacterial Agents
0
Anti-Inflammatory Agents
0
Vitamin D
1406-16-2
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
223Références
Clin Rheumatol. 2017 Mar;36(3):695-699
pubmed: 27680539
BMC Infect Dis. 2013 Jan 19;13:22
pubmed: 23331510
Immunol Lett. 1990 Jun;24(3):203-6
pubmed: 2116996
Open Forum Infect Dis. 2016 Sep 7;3(3):ofw151
pubmed: 27800526
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
PLoS One. 2013 May 08;8(5):e63840
pubmed: 23667677
Am J Clin Nutr. 2015 Nov;102(5):1059-69
pubmed: 26399865
Lancet Infect Dis. 2015 May;15(5):528-34
pubmed: 25863562
Gastroenterology. 2015 Oct;149(5):1275-1285.e2
pubmed: 26166315
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Am J Respir Crit Care Med. 2017 Sep 1;196(5):628-637
pubmed: 28692301
Trends Immunol. 2014 Jan;35(1):12-21
pubmed: 24268519
Nat Rev Immunol. 2015 Apr;15(4):255-63
pubmed: 25765201
PLoS One. 2013 Aug 05;8(8):e71116
pubmed: 23940699
Eur Respir J. 2011 Feb;37(2):376-83
pubmed: 20516049
PLoS One. 2018 Jun 26;13(6):e0198080
pubmed: 29944658
Control Clin Trials. 1996 Feb;17(1):1-12
pubmed: 8721797
Braz J Infect Dis. 2003 Aug;7(4):245-52
pubmed: 14533985
Inflamm Allergy Drug Targets. 2009 Mar;8(1):53-62
pubmed: 19275693
Lancet Infect Dis. 2009 Mar;9(3):162-72
pubmed: 19246020
Front Microbiol. 2018 Oct 30;9:2603
pubmed: 30425706
PLoS One. 2015 Sep 22;10(9):e0138340
pubmed: 26394045
Am J Respir Crit Care Med. 1999 Feb;159(2):508-11
pubmed: 9927365
BMC Res Notes. 2012 Jul 16;5:357
pubmed: 22800438
Microbiol Mol Biol Rev. 2013 Dec;77(4):608-27
pubmed: 24296574
Lancet Infect Dis. 2013 Mar;13(3):223-37
pubmed: 23369413
Chin Med J (Engl). 2014;127(17):3127-34
pubmed: 25189958
Cochrane Database Syst Rev. 2016 Jun 29;(6):CD006086
pubmed: 27355911
Int J Tuberc Lung Dis. 1999 Jan;3(1):47-54
pubmed: 10094169
J Clin Epidemiol. 2008 Oct;61(10):991-6
pubmed: 18538991
Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3071-6
pubmed: 9501217
Perspect Clin Res. 2017 Jul-Sep;8(3):132-136
pubmed: 28828308
Am J Respir Crit Care Med. 2003 Jul 15;168(2):185-91
pubmed: 12702550
J Infect Dis. 1996 Oct;174(4):727-33
pubmed: 8843209
Eur Respir J. 1994 Feb;7(2):223-8
pubmed: 8162974
Trans R Soc Trop Med Hyg. 2016 Mar;110(3):186-91
pubmed: 26884499
Proc Natl Acad Sci U S A. 2012 Sep 18;109(38):15449-54
pubmed: 22949664
J Immunol. 2007 Aug 15;179(4):2060-3
pubmed: 17675463
Front Med (Lausanne). 2017 Oct 18;4:171
pubmed: 29094039
Pak J Med Sci. 2018 Jul-Aug;34(4):849-854
pubmed: 30190740
Eur J Clin Invest. 2000 Oct;30(10):915-29
pubmed: 11029607
Lancet Infect Dis. 2010 Feb;10(2):68-9
pubmed: 20113972
Lancet. 2011 Jan 15;377(9761):242-50
pubmed: 21215445
Front Immunol. 2018 Sep 12;9:2069
pubmed: 30258443
JAMA. 2015 Apr 28;313(16):1657-65
pubmed: 25919529
J Intern Med. 2018 Sep;284(3):292-306
pubmed: 29696707
Open Forum Infect Dis. 2014 Jun 03;1(1):ofu020
pubmed: 25734093
Am Rev Respir Dis. 1993 Apr;147(4):1062-3
pubmed: 8466107
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
BMC Pulm Med. 2018 Jun 28;18(1):108
pubmed: 29954353
PLoS One. 2013 Aug 14;8(8):e70032
pubmed: 23967066
J Intern Med. 2015 Apr;277(4):373-87
pubmed: 24717092
Acta Med Indones. 2006 Jan-Mar;38(1):3-5
pubmed: 16479024
J Infect Dis. 2013 Jul 15;208(2):185-8
pubmed: 23564637
J Infect Dis. 2005 Mar 15;191(6):856-65
pubmed: 15717259
Eur Respir J. 2019 Mar 7;53(3):
pubmed: 30728208
Am J Respir Crit Care Med. 2009 May 1;179(9):843-50
pubmed: 19179490
Front Immunol. 2017 Jun 30;8:772
pubmed: 28713389